As Chicagoans Vote for Mayor, A Trauma Center And
A Presidential Library Hang in the Balance

Bookmark and Share
No trauma centers exist on Chicago's southside, where the vast majority of traumatic injuries occur.

No trauma centers exist on Chicago’s southside, where the vast majority of traumatic injuries occur.

The national discussion of whether #blacklivesmatter or which lives matter comes into sharp focus when you consider the lack of trauma centers on Chicago’s southside. That’s where the vast majority of gun violence occurs and where a trauma center is most needed. Chicagoans and community-based groups want a Level 1 Trauma Center there, and with President Obama nearly set to announce where his presidential library will be, it’s no surprise that activists are tying the library to the trauma center. Obviously, based on his biography, housing it at the University of Chicago makes sense. Anywhere else would be a stretch.

You don’t have to run a needs assessment to explore need for a trauma center. A casual glance at one of the two major Chicago papers illustrates the need well. Gunshot and stab wounds are maiming and murdering residents on the southside. Homicide Watch Chicago, a Chicago Sun Times publication counts them every day, with the byline “Mark Every Death. Remember Every Victim. Follow Every Case.” The Chicago Tribune also takes note, counting 432 homicides in 2014 and in 2015, 48, at the time that this post went up.

A Trauma Center Desert

Ask any trauma center expert. They will tell you that Trauma Centers strive to treat patients during the critical first “golden hour” after an accident occurs. Penetrating injuries need rapid attention. As few as ten minutes can make a difference between life and death. That’s when you can maximize health outcomes – perhaps preventing a death or disability. A Level 1 Trauma Center has specially trained and board-certified trauma surgeons, nurses, technologists specially trained to respond to traumatic injuries.

No trauma center exists on the city’s southside. The closest trauma center is Northwestern Memorial Hospital on Chicago’s Gold Coast (where some of Chicago’s richest residents shop and live) and the second closest is at Advocate Christ Medical Center in Oak Lawn, a suburb southwest of the city.

WBEZ clocks travel times within Chicago. A recent report found athat travel times to the closest trauma center exceed recommended standards of 20 minutes for the city. To reach a trauma center from South Shore, 76% of travel times were above 20 minute; 24% were above 30 minutes.

In Obama’s keynote address at the Democratic National Convention in 2004, he asked: “Do we participate in a politics of cynicism or a politics of hope?” It’s a question worth resurrecting now, when residents of the southside of Chicago feel like they not only live in a “trauma desert,” as the experts call it, but that public officials have also deserted them. Will President Obama desert the southside of Chicago?

From a moral and ethical standpoint, a state-of-the-art trauma center on Chicago’s southside needs to be built as soon as possible.

Austerity, Poverty, and Violence

It’s no secret that residents on the southside of Chicago feel disenfranchised. Poverty, austerity budgets, and gang violence leave people with little hope. Some extremely promising community organizing has been ongoing related to the Trauma Center launched by the group Southside Together Organizing for Power (STOP) and their affiliate Fearless Leading of the Youth (FLY), the Kenwood Oakland Community Organization, and several churches. If the names scare some of you, think of the powerlessness that those involved are trying to overcome.

Death ratesThe movie The Interrupters also does an excellent job at showing community-based efforts to thwart senseless gang violence. Surely, prevention can go some ways to improving the public’s health. But it is not enough. The coalition of groups working for the trauma center view violence prevention as complex, driven by despair, unemployment, lack of services, mass incarceration, and austerity in critically needed services, such as mental health clinics, affordable housing, and public schools.

Thus far, U Chicago Medicine has agreed that a regional solution to the trauma desert must be worked out, but publicly, it claims that it does not want to host the trauma center because of the pressure it would place on staff and financial resources.

U Chicago Medicine must be challenged. It would be simple to say that building a Trauma Center on the southside would ratchet up its debt. But in 2011, U Chicago Medicine reported $1.33 billion patient services revenue that does not include endowments, subsidies, and property tax exemptions for being a non-profit hospital. There is sufficient parkland available on the southside for a Level 1 Trauma Center at the University of Chicago along with a Presidential Library that would make the community and President proud.

Meanwhile, as this story unfolds, in the backdrop, healthcare is changing across the nation. New buildings on campuses are supporting bioscience research. Hospital beds will continue to diminish as more care is provided in an ambulatory care setting. U Chicago Medicine has a sparkling new building in Hyde Park, where it has always been. Like other academic medical centers across the United States, off campus, U Chicago Medicine has been creative in targeting programs and outreach to communities that are affluent. You don’t see them looking for patients in the Chicago Defender. New outpatient care centers are proliferating in wealthier parts of town — in many cases leaving an oversupply of doctors there. Advertisements in high-end print media and television commercials target the well insured.

Tying the trauma center to the Presidential Library at the University of Chicago would be a critical step in the right direction. No other Chicago medical entity has the resources at its hand to make this happen. President Obama and the University of Chicago need to step up to the task.

Disclosure: I lived in Chicago for many years. It strikes me far more as a “tale of two cities” than New York City, where I live today.

 

 

Posted in trauma center | Tagged , , , , , , , | 3 Comments

On Brian Williams and You and Your Doctor’s Memory

Bookmark and Share

Guest post by Blair Bolles

Memories are back in the news these days. Folks are lambasting NBC’s Nightly News Anchor, Brian Williams, as a Pinocchio, building up a record of having led a more exciting life than truth allows. Williams blames the error on a faulty memory, conflating events, but his apology was more of a poo-poo than an abject wail, “I got it wrong! How could I?”

Years ago a friend and I had a small adventure in which I was the active person and he was the tagalong. Over the years I have often regaled folks with a laughing tale of what happened. Then one day I heard my friend recall the incident and as he laughed about its details, one thing stood out for me. He was the active person and I was the unmentioned tagalong. Which of us was right?

Let me just say I have always been very confident of my memories. Sadly, confidence in one’s memory is no evidence of accuracy.

For a memory can be very clear and yet wrong. I once ran across a passage in my journal that seemed proof positive that I misremembered the timing of an incident. My reaction was not, Oh, I see. It was blank-faced amazement. How could that be? I remember the whole thing so well.

Some years ago I wrote a book called Remembering and Forgetting: An Inquiry Into the Nature of Memory, which forced me to spend a year or so investigating the topic of memory. It left me doubting not just mine, but everybody’s memory. I learned that remembering is not like pulling things out of a database; it is much more like a creative act of imagination, in which a person’s biases, moods and assumptions shape the product. Also important is how closely you paid attention. Chances are, if the doctor tells you you have cancer, your attention will wander away from the rest of the medical report. You will have no reliable memory of the rest of the news.

Here’s a funny story about my book. Some years after it came out I was at a dinner party where one of the guests had not only read the book, but he added that he loved it. It turned out he was a professional memory expert who made his living teaching people how to remember names. He said to another guest that he loved my book because it was so different, unlike any other book on memory he had read before. “It opens…” he told the listener, and then he stopped. He couldn’t remember the opening of the book that he was busy praising, and he was the memory whizz, able to meet 55 people and recall their names at a glance.

So let’s not be so cocky and insistent that somebody must be a liar because after all how could he forget something like that? We are the heroes of our lives and we remember ourselves as actors amid tagalongs. We are impressed by surprises, but really complicated surprises (like a unique book) are hard to remember, just because they are surprising and don’t fit into the ready-made molds.

Part of every person’s education should include strong and convincing lessons in memory’s fallibility.

Doctor’s should not just write everything down; they should consult their notes every time. And they should not expect their patients to remember what was said. Written or video copies of the same information should be part of any medical advice. And as Brian Williams is being reminded, journalists too should consult their notes. When preparing a news story, Williams would not have accepted the uncorroborated memory of a stranger; he should not have accepted his own memory either. But that advice is hard to take.

 

Posted in memory | Tagged , , , , , , | 10 Comments

Seeing Your Doctor for Prevention,
Treating On Your Own: A Report from the Field

Bookmark and Share

First off, let me be clear: what I report below I am not recommending. My first obligation is to my readers. Also, I am grateful to Brooke Binkowski, a stellar journalist-friend, who spontaneously emailed me this story this morning. It arrived in my inbox amid a heated social-media discussion about who the real villains are in the failure to vaccinate. Also, why is it we can’t reach them. Are they the rich and entitled, the libertarians, the natural, organic folk, or who?

Sometimes, you hear a story and it makes you want to use it while it’s hot. This is a gem of a story, but it’s not really about vaccines very much. If you like it, you might want to follow Brooke at @brooklynmarie. She has a lot of great stories up her sleeve.

Here’s what Brooke wrote:

Because of who I am and where I live, I collect old hippies, you know, I feed them, talk to them, hang out with them… one of them stopped by yesterday, he’s about 70, an ex-drug runner, never has taken care of his health, has diabetes, and has had major heart surgery last year (I went to see him in the hospital.)

Anyway I said: “How have you been? He said, “Oh, I’ve been fine. I ran into complications recently, did something to my pinky toe, so I cut it off.” I said, “I’m sorry – you had it cut off?” He said “No, I cut it off myself, just nipped it off with a pair of pliers, wanna see?” (of course I did, I am one of those people)

So he’s showing it to me, it’s healing nicely, etc, and I say to him, well what happened? He said: “I’m diabetic, it was getting gangrenous, just wasn’t feeling it, so… also I decided to go off my heart meds, they were making me feel like crap.” So this guy, the ex-drug runner who cuts off his own toes and now lives out in a boat on the marina. He has a daughter. Guess what?  He got her vaccinated.

Man holds pliers to his toe. This is a likeness,  This toe is healthy and was left alone.

Man holds pliers to his toe. This is a likeness, not the toe or the man in the story.This toe is healthy and was left alone.

Posted in Patient stories | Tagged , , , , , | 2 Comments

Nursing Homes for People of Color:
Still Segregated, Still Unequal

Bookmark and Share
Benzena Tucker (center) spent the last few years of her life in a public nursing home with peeling paint and overworked staff. She had no family and had been too ill to work for many years. At her side, are two volunteers, Wendy Josephs (l.) and Ricki Lewis (r.).

Benzena Tucker (center) spent the last few years of her life in a public nursing home with peeling paint and overworked staff. She had no family and had been too ill to work for many years. At her side, are two volunteers, Wendy Josephs (l.) and Ricki Lewis (r.) Benzena provided permission to publish this photo.

If Martin Luther King, Jr. was alive today, he would be 86. If he was like many elderly black Americans, he might well end up in a nursing home ranked lower in quality and with less well-trained nursing staff than a nursing home that many white Americans reside in. The facility would likely house a disproportionately larger proportion of people of color and on Medicaid than higher-quality nursing homes.

The disparities are easy to miss. After all, what happens in nursing homes stays in nursing homes, invisible to the rest of us. The only ones who see what’s going on are the patients, family and friends, and staff. If people report lousy conditions in the homes, nursing homes often vilify them. In fact, some would argue that the industry hides behind a smokescreen of patient privacy. Yes, there are inspections. Are they sufficient to drive equal care? Apparently not. Overall, the nursing home industry has changed little in terms of providing quality care for minority elders on par with what white elders get.

Documentation of inequality in long term care for minority elders dates back to enactment of Title VI of the Civil Rights Act and the passage of Medicare in 1966, which prohibited segregation in health facilities that accepted federal funds. In 1981, an Institute of Medicine report addressed the issue of segregated care in nursing homes. The hospital industry was forced to integrate to some degree at least, but nursing homes have been left largely alone.

Contrary to stereotypes, a large Commonwealth Fund analysis led by Vincent Mor, PhD, from the Department of Community Health at Brown University, found that segregation was lowest in the South and highest in the Midwest (Wisconsin, Missouri, Michigan, Indiana, and Ohio). The study found that Cleveland, Ohio, followed closely by Gary, Indiana, were the most segregated cities for nursing homes. Additionally, black elders tended to be in nursing homes in the lowest quarter of quality ratings. Blacks were 1.7 times as likely as white Americans to reside in a nursing home that was subsequently thrown out of the Medicare and Medicaid programs because of poor quality and 2.64 times as likely to be in a facility housing predominantly Medicaid residents. Elderly black Americans are not the only groups at increased risk of going to a poor-quality nursing home. So are elderly Hispanics and probably many other groups not cited here.

The proliferation of for-profit nursing homes in an industry that was once largely nonprofit has also had adverse impacts. In this study, for-profit nursing homes have been found to have lower RN staff intensity and lower RN skill mix than nonprofits, jeopardizing patient care. Poor people on Medicaid are going to for-profit nursing homes at far greater rates in many parts of the country.

This post is a snapshot of one part of long term care, which is an immense, complex topic.

Readers would be misguided if they thought that disparities are concentrated in the Midwest and do not persist elsewhere. These two anecdotes, though not data, are telling. Friends of mine recently watched in tears as a dear African American male friend landed for a long stay in a one-star nursing home in New Jersey. The nursing home housed people of color on Medicaid primarily. My friends were inconsolable when they returned from a visit, quick to call it a “crowded, smelly, dumping ground.” I learned of another story from an older African American woman from Queens NY, a New York City government retiree. I worked with her for many years. When she felt that she could no longer keep up her house, she could not find a satisfactory long term care residence to move into. She never left home: her health deteriorated and eventually, she died at home.

These stark realities are shameful. It’s 2015. We can quibble about statistics, question cause,effect, or association, but outrage, remedies, and stiff penalties and incentives for change are desperately needed.

Posted in aging, disparities | Tagged , , , , , | 8 Comments

Happy Dogmatic New Year’s: Here’s How You Lose Weight

Bookmark and Share

I don’t have any magic bullets on weight loss to show you here, but in the spirit of this blog, I give you some voices from the street.

When the topic of weight loss came up in a phone call yesterday, a close friend advised: “Don’t make anything too interesting or tasty…because if you do, you are liable to overeat. Keep it simple. If it takes work, just forget about it.” She is using a grit-your-teeth and just do-it-strategy. This approach has a certain appeal to me. Why pretend that you are embarking on a fun adventure when you are not? I’ll probably incorporate some of this…that is as long as I can stand it.

I’ve learned a lot about portion size, tracking, not missing meals, and such over the countless forays into the world of weight loss over my years. So I’ve got some basics.

Remember those days of “eat at least five fish meals a week” with Weight Watchers…oh did I lose!! But by the third day of the third week, I thought I developed arthritis of the mouth. With a forkful of fish in my mouth, I couldn’t chew. I nearly threw up. (a feat when there is nothing in your stomach to bring up)

Yep, there’s tons of stuff out on keeping it simple, packaged foods, and prepare ahead. Another idea that my friend suggested was to: “Just buy prepared grilled chicken breasts.” She says that they are everywhere, but somehow I’ve never noticed. Recommendations anyone? She didn’t point me anywhere.

Now we’ve got the new fad: exercise in 10-minute spurts. I am eager to see how that advice pans out. But for inherently sedentary me, I might give it a go.

Another person recommended the app myfitnesspal.com. I signed up yesterday (apparently before, but I only discovered this when I tried to open a new account) …and I am so conflicted about these apps and mobile tracking. You’ve got Eric Topol running around pitching them like they are the penultimate answer to health, happiness, and the end of doctors. What does he know? I am skeptical about taking advice from anyone that tall and lanky. Then skeptics like Harlan Krumholz question the data…you have to realize that Topol and Krumholz are not weight-loss gurus. We live with uncertainty.

Then I’ve got yet another friend who says: “You don’t need those apps. Just exercise and eat right.” That’s easy for someone who just naturally loves being fit and eating healthfully…but I DO NEED SOMETHING.

I am resisting the hucksters, entrepreneurs, and evangelists…although I am still tempted by some magic item, say a Bosu ball. Anything bigger than 12 x 12 won’t fit into a New York City apartment.

Remember those old Jack LaLanne machines where you could stand and they’d claim to just grind all the fat away from your thighs if you could stand the friction…if only. You can hope.

I can’t stand the idea of paying big bucks to some weight loss center (and they are growing in leaps and bounds) or support group when I could run these places. I don’t have the bucks…and oh, there’s the regression back to baseline and worse.

I think you have to have a certain sense of humor about yourself, your fat self, and trying to lose weight. I wish we could laugh about it together a bit more – and stop being so judgmental. Plus people need to be nice to you and not offer gratuitous advice. We need some new ideas, nothing dogmatic as far as I am concerned, better ways to compassionately be together. Some more spontaneity, originality, that doesn’t involve paying out – how about that?

Posted in obesity | Tagged , , , , | 6 Comments

2014 Drug Issues: Where’s the Data, Product Hopping, Inappropriate Use, and What’s Come and Gone

Bookmark and Share

For 2015, I’d love to see headway in clamping down on drugs that don’t work, tighter regulation of inappropriate drug marketing, and more open data and transparency from industry. Is it pie-in-the-sky? Maybe. But let’s work towards it.

Patients need to be skeptical before pushing for a prescription or filling it. I’d urge you to search news accounts or blogs like mine on drugs that you are prescribed before you fill your next prescription. You might be enormously surprised and think twice before you grab your next Rx. You can send me questions on twitter @lauranewmanny or in the comments here. Below, I point to issues with specific drugs, more emblematic of the drug world than case examples that stand on their own.

Tamiflu (the antiviral drug oseltamavir for influenza) and the struggle for open data

It’s flu season and the flu vaccine will not cover some of this year’s flu strains. That still means that you should get a flu shot because the flu can be deadly. If you get the flu, you might be tempted to reach for Tamiflu, which is marketed all over television in the United States, pushed by the Centers for Disease Control and Prevention, but questioned by many respected health authorities. Massive stockpiling of the drug happened in the US and around the world. According to the US Government Accounting Office, the US spent about $1.3 billion on developing and stockpiling flu drugs like Tamiflu.

Leading the charge against Tamiflu are Yale’s Harlan Krumholz, MD, Ben Goldacre, MD, from alltrials.net, and the Cochrane Collaboration, the independent, global healthcare research group that performs evidence-based reviews. Krumholz summarized five key objections to the rampant Tamiflu marketing in Forbes: pointing out that 1) Tamiflu’s manufacturer, Roche, did not perform independent trials, nor were they independently vetted, and just 60% of randomized trial was released; 2) Tamiflu has demonstrated no benefit in reducing hospitalizations for the flu; 3) No conclusions from the trial data can point to reducing severe complications; 4) None of the data available back a benefit in terms of reduced transmission; and 5) At best, Tamiflu may reduce symptom duration by about less than a day.

After substantial publicity and hammering from these groups, the Cochrane Collaboration obtained a more complete data set and took a second look at the evidence on Tamiflu.In April 2014, Cochrane published its review, which held that “there is no good evidence to support claims that it reduces admissions to hospital or complications of influenza,” but that it did shorten symptoms of flu by half a day.

Fiona Godlee, BMJ Editor in Chief described the persistent efforts to get Roche to release all the data this way:

“This review is the result of many years of struggles to access and use trial data, which was previously unpublished and even hidden from view. It highlights with certainty that future decisions to purchase and use drugs, particularly when on a mass scale, must be based on a complete picture of the evidence, both published and unpublished. We need the full data from clinical trials made available for all drugs in current use. With the new European Clinical Trials Directive bringing in rules for future drugs, it highlights the enormous challenge we face. We need the commitment of organisations and drug companies to make all data available, even if it means going back 20 years. Otherwise we risk another knee-jerk reaction to a potential pandemic. And can we really afford it?”

Next up, I consider Namenda (memantine), approved for moderately severe to severe Alzheimer’s disease or dementia.

Last week, following an antitrust suit initiated by New York’s Attorney General Eric T. Schneiderman, a Federal judge issued a preliminary injunction that would stop Actavis, who markets Namenda, from retiring an older form of its drug to make way for a newer, more expensive form with a longer patent life.  Namenda costs about $1600 a year.

What pharma was trying to do is what is known as product hopping, where companies attempt to head off purchase of an affordable generic by eliminating the older brand. Thus, generics for the older drug cannot be made. It’s profitable — yes, but in patients’ interests, it’s doubtful.

Product hopping is a huge issue – not just for Alzheimer’s drugs, but it cuts across many drug categories. If you notice it happening with your drugs next year, check in with your elected officials, your State Attorney General. They just might be interested.

Another issue with Namenda is off-label use. It is prescribed to patient groups for which there is no proof that it works. In 2006, nearly 20% of the patients in the United States diagnosed with mild Alzheimer’s or dementia were prescribed Namenda, despite data showing that it is not effective. It’s not surprising that families are primed for Alzheimer’s drugs, given how feared Alzheimer’s and dementia are.

This post won’t review the evidence and clinical trials, but you can check out this in a paper authored by Dana Casciotti, PhD. The paper does a very good job of summarizing how overused and inappropriately used Namenda is relative to what has been shown in the studies performed to date.

Provenge

In yet another category, the prostate cancer vaccine Provenge, approved for metastatic hormone-resistant advanced prostate cancer, never caught on. In November 2014, Dendreon, makers of Provenge, filed for bankruptcy. Dendreon’s sole product is Provenge. Although the company promises to keep Provenge available, it had a rocky start from the beginning.

During the FDA approval process, it was mired in controversy and it is fair to say that urologists never became enamored with it. When I attended the annual American Urological Association’s annual meetings in 2007 and 2008 as a reporter, many urologists told me that they thought Provenge was going nowhere. These issues are covered quite well in the Cancer Letter in 2007 (behind a paywall), but the Cancer Letter offers excellent coverage.

Patient advocacy groups clamored for the drug’s approval. Also, given that treatment options for hormone-refractory advanced prostate cancer were limited to docetaxel, which had severe sides effects and only added 2 to 3 months to overall survival, the far less toxic Provenge, looked desirable.

In the early trials, several methodological concerns about the drug’s effectiveness were raised, including the failure to meet the phase III study’s primary endpoint, the claim of improved overall survival depending on a post-hoc analysis, as well as questions about the FDA’s approval standards changing in the middle of the approval process. Finally, a larger confirmatory phase III trial of Provenge, published in the New England Journal of Medicine, showed that median survival increased by over four months, compared with placebo. Provenge met muster for FDA approval in 2010. A full course of treatment cost about $93,000, which Medicare was covering at the outset, but private insurers resisted. Putting all these factors together, Provenge simply never caught on.

In closing, I want to emphasize that there are a huge number of drugs that I could have covered here. Obviously, this post is far from complete. If you find it helpful, let me know. I will cover more of these issues in 2015.

More importantly, if you like what you are reading, consider a donation to this independent blog (upper right on the front page). I spend hours researching this material and am compensated zip. I hope to bring an iconoclastic perspective and content that helps you make the best health decisions. Posts have become less frequent simply because I need to make a living, this blog is not monetizing, and no funders have risen to help out. I hope that you seriously will consider contributing.

Finally, best wishes for a healthy and happy new year! See you all after the first of the year.

Posted in drugs | Tagged , , , , | Leave a comment

Don’t Be Too Quick to Diagnose Yourself

Bookmark and Share

Learning all you can to manage your health is clearly a good thing. Today we have more at our disposal to learn a huge amount about our health status, how to intervene to avoid a crisis, and optimize our health. But recently, I’ve seen friends make assessments of their health status that were dead wrong. One could have died. Another might have had cancer, but she thought otherwise. Maybe their doctors would have missed the seriousness of these symptoms too, but I have to hope that, in the right hands, they would do better than you and me.

When a Symptom is Thought to Be Part of a Chronic Condition

A close friend of mine who has had MS (multiple sclerosis) for decades has suffered from MS fatigue, a well-known issue for people with MS. To some extent, there is some nihilism about the fatigue in the MS community. According to the National Multiple Sclerosis Society, fatigue occurs in about 80% of people with MS. The Society cautions that outsiders may misread the symptom as “depression or not trying hard enough.” In addition, the MS fact sheet makes it clear that there is no scientifically proven treatment to deal with this symptom. So letting it be may be what people with MS do.

But while my friend was visiting, I watched him make that miscalculation, attributing fatigue to a flare or worsening of his MS. He could have died. Two weeks ago, I met him at Penn Station, for a weekend visit. He looked bushed. I immediately grabbed his suitcase and got no resistance. We went for a meal and he talked about his “MS fatigue.”

We learned the hard way that his fatigue had nothing to do with MS. He reported bouts of dizziness. We stopped to sit down several times when he was walking. Two hours later, he fell down on a NY Subway platform. When EMS got to him, his blood pressure was down to 70/40 and he was rushed to an ICU. There, the doctors spotted a serious electrolyte imbalance. He could not have managed any of this on his own. We are all thankful that he is alive and for the hospital and emergency medical care that he got.

The culprit in the collapse appeared to be a change in his blood pressure medication. Weeks ago, his doctor had added on a second medication because the first medicine didn’t control it. That medication proved ineffective so the doctor substituted another. It brought his blood pressure down too far. After he was stabilized and rested in New York, I accompanied him home, which is out of state. He’s not out of the woods yet. He still has his blood pressure pills to sort out, which he is doing with his doctor on a schedule that the doctor, not him, is arranging. He doesn’t need another health crisis.

What Looks Like Belly Fat Is Not

I also watched a dear friend attribute her bulging abdomen to postmenopausal weight gain. Never mind that she is serious about exercising and eating nutritiously. Are women so hung up about weight that we cannot realize when a change in our bodies is concerning?

What finally got her to a doctor when a friend noticing a far more swollen abdomen after not seeing her for one month.

The result: she had an 18-pound benign ovarian cyst. Here’s a similar story that articulately shows how women are quick to attribute abdominal bulge to weight gain.  Thankfully, both women had the cysts removed. In both cases, the cysts could have masked cancer.

Not Everything is A Thyroid Problem

In my own experience, I have wrongly attributed feeling hot and cold, fuzzy, or confused to my thyroid being out of whack. Like many women, I have hypothyroidism that is corrected with thyroid medicine. I have certainly had to make changes to my  medicine over the years. But this year, I learned that a urinary tract infection was the likely source of the hot-and-cold and fuzziness – and not my thyroid. I’ve seen older women in nursing homes get loopy with a urinary tract infection, with doctors simply guessing it’s dementia. Like fatigue and feeling fat, feeling hot and cold or fuzzy feels nonspecific, vague, and innocuous symptoms – perhaps something to put aside – or something that it is not at all.

Recognizing the Problem

The patient empowerment movement has made great strides in educating people about illnesses and helping us optimize our health and medical decisions. But there are limitations that we need to be cognizant of. If my fatigued friend with MS had not gotten to the hospital in time, he could have died. How long would it have taken my friend to see a doctor about her large, possibly malignant, ovarian cyst? Do we really always have the best medical information to analyze our symptoms? Can we read laboratory results and radiology scans as well as our doctors? Yes, we should have all that information because it is our’s and valuable in disease management, but having information at hand is not tantamount to knowing medicine.

 

Posted in self diagnosis | Tagged , , , , , , , | Leave a comment

In Stunning Reversal, Unnecessary “Preventive” Mastectomies Are Surging in Young White Women with Insurance

Bookmark and Share
Breast anatomy. Source: Wikimedia Commons.

Breast anatomy. Source: Wikimedia Commons.

I remember the first time that I heard about an unexpected rise in unnecessary mastectomies in young white women, who were privately insured. About five years ago, I was at the largest cancer meeting of the year, the annual meeting of the American Society of Clinical Oncology. Speakers raised the issue; they’d speculate why; and within minutes, the speaker and the entire audience looked crestfallen and helpless.

For many, it was a devastating turnaround. The women’s health movement and progressive forces in medicine had vigorously fought for breast-conserving surgery because the best science long ago proved that total mastectomies were overkill. Not only has breast-conserving surgery been tested rigorously against total mastectomies, but the results have consistently shown, that for women with early breast cancer, there is no survival advantage to having more aggressive surgery. Compelling proof that breast-conserving surgery AKA lumpectomy and radiation should be the standard of care for early breast cancers goes back until about 1990. Simply put, for women with early breast cancers, if both breasts are removed, they will not reduce their chance of getting cancer again, nor will they improve their survival any more than if they had had a minimally invasive lumpectomy followed by radiation. Additionally, unnecessary hysterectomies were also questioned and they are far less common today.

In the larger picture, organ preservation is a big part of medicine today, and often, for very good reasons. For example, for many early-stage kidney cancers, taking the entire kidney out is now considered excessive and harmful because it elevates a patients’ risk for chronic kidney disease and cardiovascular disease.  Clinical practice guidelines call for reviewing each kidney cancer case with an eye towards which people have organ-confined cancers,  can safely have a limited part of their kidney removed, and avoid chronic devastating conditions.

I’ve seen friends, daughters of friends, siblings of friends, and moms die from breast cancer. But I’ve also seen far more women in recent years who have had lumpectomy and radiation, get regular monitoring, who do quite well. Also breast cancer treatment has changed dramatically so that outcomes from decades ago may not be comparable to today. I don’t blame any woman for thinking that a mastectomy is what she wants after she hears a breast cancer diagnosis. Intuitively, a woman might think, the more removed, the better.  However, it is not straightforward. I am also sure that I would become terrified.

Susan Love, MD, Chief Visionary Officer, Dr. Susan Love Research Foundation, Santa Monica, CA,  describes how fraught with fear deciding what to do is. “This is the one of the only decisions that women with breast cancer will get to make. Women who hear ‘cancer’ think it is a potentially fatal disease. You just don’t think rationally.” Love also can understand why many women think that “the more aggressive the surgery, the better.”

High-risk women could benefit from more aggressive surgery, but they are not your average woman. For women who have mutations in the BRCA genes or a strong family history of first-degree relatives with breast, all of which can be sorted out with cancer prediction models, this story does not apply. Angelina Jolie was one example of a woman who had an 80% of developing breast cancer. For women with these risks, a preventive mastectomy and removal of ovaries will make sense.  Exactly what constitutes high risk will be addressed in a subsequent post.

Eleanor Walker, MD, Director of Radiation Oncology at Henry Ford Health System in Detroit, MI, stresses that taking time with patients is critical. “Young women can expect a healthy lifetime of at least 50 years. Lack of knowledge has to be addressed. There are family issues to address.”

Walker described an “options clinic” at Henry Ford for women who are newly diagnosed. “We need a lot of education for patients to understand that whatever they do, there are no guarantees.” Although reports have been out that address getting a second breast cancer in the unaffected breast, Walker points out: “In 10 to 20 years, if there is a recurrence, it is most likely to be in the same breast. Only the highest risk women are likely to develop breast cancer in the opposite breast.”

The Latest Research and Public Policies

What cancer doctors could only hint at a few years ago came into stark view with the publication Sept. 3 of a large study of double mastectomies in California women between 1998 and 2011.  Using data from California’s Cancer Registry, which collects data on all the patients diagnosed with cancers in California since 1998, investigators provided a wake-up call on the jump in double mastectomies:

  • Of nearly 200,000 women diagnosed with breast cancer since 1998, in each year, between 1998 and 2011, double mastectomies rose by about 14%.
  • Women who had a double mastectomy had no better survival rate than those who had the more conservative lumpectomy.
  • The proportion of double mastectomies in women among women with a diagnosis of breast cancer soared from 2% in all patients with a breast cancer diagnosis in 1998 to 12.3% in 2011.
  • For women under age 40, just 3.6% had both breasts removed in 1998, but this jumped to 33% in 2011.
  • Women who had a single mastectomy (just one breast removed) had slightly worse survival than women who had lumpectomies or double mastectomies.
  • Double mastectomies were more common in National Cancer Institute-designated facilities.

Far less clear are who chooses total breast reconstruction, either at the same time as the mastectomy, or delayed, and who do not. “Women need to know that the Women’s Health and Cancer Rights Act passed in 1998, provides protections for women who want total breast reconstruction,” said Otis Brawley, MD, Chief Medical and Scientific Officer of the American Cancer Society.

Women's Health and Cancer Rights Act of 1998

Women’s Health and Cancer Rights Act of 1998

That includes not only total breast reconstruction on the affected breast, but surgery and reconstruction of the other breast to produce a symmetrical appearance, prostheses and physical complications at all stages of mastectomy, including lymphedemas. However, for certain demographics, practitioners and linkage systems are not in place.

Brawley pointed out that  80% of plastic surgeons do not take Medicaid or the uninsured. In fact, perhaps in large part because of this, at some hospitals serving poor, minority women, total breast reconstruction is not even discussed.

However, young, insured, white women are more likely to get their cancer care at an NCI-designated facility and they will  find it much easier to get total reconstructive surgery, according to Love . “It’s far easier to coordinate care if the general surgeon is linked to a plastic surgery team so that if a woman wanted breast reconstruction, they can work together,” she said.

In one sense, there may be a silver lining in terms of how black women fare in some aspects of breast cancer care. Otis Brawley,  commented:

“When something is a new fad [for example, getting unnecessary double mastectomies], the poor and disenfranchised always end up being better off. It was like that when women were going for bone marrow transplants.”

Bone marrow transplants subsequently proved useless.

On Sept. 4, a team of University of Chicago researchers presented a paper at the American Society of Clinical Oncology’s Breast Cancer Symposium 2014  in San Francisco that provided more insight. They surveyed women who had chosen a double mastectomy before surgery, finding that those women were far more worried about recurrence, had higher anxiety levels, and less knowledge than those not considering it. Many stated that the diagnosis “sent them into a daze.”

I am Not My Breast

Besides fear, anxiety, or poor information contributing to health decisions, I can see why movements are afoot with the MO “I am NOT my breast.” I too don’t want to be objectified. As more news surfaces on an epidemic in rapes, anger about rape justice escalates. In a hostile sexist climate, it makes sense that some women might say the heck with my breasts. They might be more trustful of their instincts and their allies than outside authorities. For example, in Atlanta, African-American women have joined forces to create a group called Bold and Breastless. 

 Coming Full Circle

In an ironic twist, the trend towards breast-conserving surgery goes back to some of the nation’s first women’s health advocates, including Our Bodies, Ourselves, as well as many other grassroots women’s health groups around the country, and advocates, especially Rose Kushner. In 1975, Kushner wrote the landmark book and bestseller Why Me: What Every Woman Should Know About Breast Cancer to Save Her Life. (It was originally titled Breast Cancer: A Personal History and Investigative Report.) Kushner was one of the strongest voices against disfiguring mastectomies.

Taken together, since the 1970s, women’s health advocates have argued against violating women unnecessarily, questioning not only unnecessary mastectomies, but hysterectomies, the safety of the first birth control pills, and much more. Self-education and getting the best information to women have been part and parcel of the women’s health movement for decades. Inside the medical profession, progressive individuals continue to question unnecessarily harming women and pressing for science to guide practice.

I don’t know whether and when the trend towards unnecessary preventive mastectomies among young white women with insurance will change. Maybe each generation has to see for themselves what makes sense.

I will say this: like it or not, insurers have demonstrated increasing concern with eliminating excess procedures that offer limited or no proven health benefit. Double mastectomies are costly and studies have consistently favored breast-conserving surgeries for early noninvasive breast cancers. If insurers go after it, public debate will pit a rising group of outspoken women up against the medical establishment and insurers. Sorting this out will not be easy.

 ###

Next on PatientPOV: Celebrity Breast Cancer War Stories

Within the past two years, three celebrities have gone public with their breast cancer stories: Good Morning America anchor Amy Robach, the comedian Wanda Sykes, and actress and director Angelina Jolie. What have they contributed?

 

 

Posted in breast cancer | Tagged , , , , , , , , | Leave a comment

A Second Look at the European Randomised Study Of
Screening For Prostate Cancer

Bookmark and Share

Last week, The Lancet published 13-year follow-up results from the European Randomised study of Screening for Prostate Cancer (ERSPC), an international trial of PSA testing in seven countries (the Netherlands, Belgium, Sweden, Finland, Italy, Spain, and Switzerland). (Unfortunately, the complete study is behind a paywall.) The core finding reported was that after 13 years of follow-up, prostate cancer screening cuts deaths by about 20%. However, the investigators concluded that screening should be rejected pending “further quantification of harms,” with their elucidation “a prerequisite for the introduction of population-based screening.” Fair enough.

Even though the results were covered by more than 100 news outlets internationally, absent from the many reports were critical questions about the trial that speak to the trustworthiness of the findings. Study limitations were also given short shrift by the trial investigators and the editorialists.

In proceeding with this story, I learned first hand that even though outsiders reviewing the study pinpointed flaws, they placed near the top praise for the study’s conclusion, that screening be looked at skeptically, based on the knowledge base today.

Here, I take the liberty of sharing the pitfalls, believing that for patients to view screening without bias, honest communication, however complicated, is imperative.

What I learned about the trial sure startled me.

Just Two of Seven Countries Showed a Screening Benefit

Reviewing the trial for PatientPOV.org, Anthony Zietman MD, immediate Past President of the American Society for Radiation Oncology, and Professor of Radiation Oncology at Harvard Medical School, raised this question:

“An unexplained aspect of this multinational study is that the “benefits” of screening were seen in Holland and Sweden, but not in any of the other half dozen European nations contributing patients. Explain that if you can! I know I can’t.”

In an email, Peter Albertsen, MD, Professor of Surgery, University of Connecticut Health Center, Farmington, CT, explained it this way:

“Swedes have a very high incidence of prostate cancer –higher than the rest of Europe and equivalent to US African-Americans. Screening works better the higher the incidence of disease. The Holland study was barely statistically significant. Some have argued that the screen detected cases were treated more aggressively. The big question is Finland. They contributed the most patients, but screening made no difference. They took a population-based approach, rather than Holland that invited men to participate before enrolling them in the study. In all the other countries, the sample sizes were too small. Therefore there was insufficient statistical power.”

American Cancer Society Chief Medical Officer Otis Brawley, MD, amplified issues surrounding the findings in Finland. Like Albertsen, he pointed out that the Finnish component of the trial was negative. “It was the largest part of the trial and Finns have a high rate of prostate cancer as well.”

In addition to the pitfalls noticed above, Brawley said:

Sweden had an unusual non-straightforward randomization that biases toward a finding that screening works. The control group was never informed that they were in a clinical trial. They randomized census rolls. This means that men with metastatic disease at the time of randomization on the screen arm got to opt out, while men in the control arm did not.

Moreover, Brawley questioned whether those in the control arm had the same access to quality of care as the screened arm:

“The screened individuals were treated by experts running the study. The control group got whatever was in the community.”

Brawley considers some of the issues in the trial so troubling that he has called for independent external review of the trial.

Praise for Investigators Opposition to Screening

Opposition to population-based screening has grown in recent years and commentators in this story praised the study’s conclusion as well. In an email, Brawley wrote:

“I agree with that [the conclusion] and it’s consistent with a number of current recommendations, including the American Cancer Society and the US Preventive Services Task Force, which are against ROUTINE screening, but speak positively toward true informed decision-making. The benefits are possible, but are small if they exist, as several studies have shown.”

Albertsen added:

“This study and the recent SPG-4 [Scandinavian Prostate Group 4] results are actually quite consistent.  PSA testing does find some prostate cancers that are eventually fatal.  Radical prostatectomy does cure some prostate cancers that would have been fatal. But in the process of detecting these cancer, a large proportion will not progress, hence overtreatment occurs. In addition, when doctors find very aggressive cancers, they are especially lethal and treatment does not alter outcome. So screening works for some cancers, but not for others.  Now the problem is how to tell these two groups apart.”

Nonetheless, rejection of prostate cancer screening remains a bitter pill for many Americans to swallow. Some question whether they are trading a risk for death from cancer with harms that they think simply don’t compare.

There’s plenty more that has to be done if doctors and patients are going to get on the same page. A lot of work is underway to engage patients, share evidence-based data, and ratchet up understanding of the benefits, risks, and uncertainties.

These are complex issues and they don’t fit well into a simple slogan or headline. In writing posts like this, sharing what I hear patients saying about these issues, I hope to help bridge some of the gaps in understanding, further best care, and set in motion making informed choices.

NOTE: This post is the first of a series. There is a lot to discuss and I am interested in hearing from patients interested in these issues. I’ll try to get the next installment out before my summer vacation, but it may lapse until after Labor Day.

I invite you to comment below, tweet the link to the story, ask me about this on twitter @lauranewmanny, and by all means, like my Facebook page and discuss this there, and/or in comments below . I’d like to engage you all in further discussion.

Posted in Prostate Cancer | Tagged , , , , | Leave a comment

4 Short Summer Reads: Concussion in Girls, Adult Diapers,
Gay Conversion Therapy with Electric Shock, and Chronic Pain

Bookmark and Share

We’re halfway through the summer, when perhaps you have more time for reading and considering new ideas. I want to draw readers’ attention to four issues that sharpen the focus on overlooked population groups that should be part and parcel of patient-centered research and care. Presented in no particular rank order, I think that they are all worth thinking about:

1. Concussions in girls’ sports. Last fall, I wrote about concussions in school sports, sometimes resulting in long-term head injury. I asked whether culture change, involving taking kids off the field, teaching parents and coaches how to recognize concussions, and getting independent medical evaluations will be accepted and help avert long-term traumatic brain injury. Unfortunately, the story was focused largely on boys and male professional athletes. After I wrote the story, a reader approached me privately and said that I was remiss in excluding girls. Soccer is the leading sport for girls’ head injuries.

I was pleased to see a commentary in JAMA Pediatrics this week by Cynthia LaBella, MD, on concussion and female middle school athletes. The piece reviews a prospective cohort study of middle school female soccer players between March 2008 and May 2012 by John W. O’Kane and others, from the University of Washington Seattle. Concussions in middle school are studied less frequently and girls and women in sports are still not that visible in mass media despite the passage of Title IX, which aimed to end discrimination and build inclusiveness for females in sports, in 1972, more than 50 years ago.

Notably, the Washington state analysis found that:

  • younger girls are more vulnerable than older ones;
  • heading causes most of the concussions;
  • nearly 60% of girls played despite symptoms, and
  • less than half sought medical attention.
CDC-recommended Heads-Up app, in IOS and Android.

CDC-recommended Heads-Up app, in IOS and Android.

What is especially striking is that these figures follow Washington becoming the first state to pass concussion legislation in school. Clearly, more concussion awareness and early diagnosis is warranted, according to LaBella. But, in my opinion, for real culture change, we may need to look at carrot-and-stick incentives. Anecdotal data tells me that parents and coaches are reluctant to pull kids out of sports.

Adult diaper use now supplants baby diapers. Large population shifts are afoot, as this Wall Street Journal article nicely highlights, by illuminating a major shift in sales of  diapers. Adult diaper sales now outpace sales of baby diapers (up 20% versus down 8%. respectively). This parallels a drop and leveling off of the birth rate and boomers aging. Marketers are focusing on this booming 65+ market. I’d love to see this aging population actively engaged and accommodated in patient-centered research and practice. Please send me information on efforts to engage these patients.

Using electric shock for gay conversion therapy.

Bans on gay conversion therapy in the United States are proliferating at last, which is good news. Yet many other countries remain in the dark ages.

 

Electroconvulsive therapy (ECT), National Institutes of Mental Health, NIH.

Electroconvulsive therapy (ECT), National Institutes of Mental Health, NIH.

A shocking story in Friday’s Washington Post reports that gay activists in China are suing to stop electric shock therapy to “cure homosexuality.” Homosexuality is closeted in much of China. A quote from the Chongqing Center, which employs electric shock points to this attitude:

“The Chongqing center explains its views of homosexuality on its Web site: ‘Any type of homosexuality is not really homosexuality. It’s just a wrong way of sexual release. They just need to be guided.”

Taking a strong stand against the violence against GLBT groups around the world is imperative if this is to stop.

Stigmatizing, humiliating reactions to chronic pain. How do we balance the chronic pain against an epidemic of opioid abuse? Not very well, writes Janice Lynn Schuster, in “Down the Rabbit Hole: A Chronic Pain Sufferer Navigates the Maze of Opioid Abuse.”  Schuster describes how bothersome pain in her tongue, felt as throbbing, burning, and pain upon eating and speaking, led to a tongue surgery that made her pain far worse. Schuster questions herself for not reviewing the outcomes online with this surgery, but the bulk of the piece deals with her frustrating search for pain relief without judgment.

It’s a compelling read, pointing to a labyrinth of pain management, difficulty returning pain pills that didn’t work, hurdles filling essential prescriptions, and a “confused national response to opioids.” “Waiting for better days,” she remains “furious” at the stigmatizing and humiliating responses she has gotten from doctors and pharmacists. “Surely,” she concludes, “for all our yearning to understand both [pain itself and the experience of seeking treatment for the pain], we can find better ways to ease the suffering and devise treatments and strategies that do more good than harm and that do not shame and stigmatize those who suffer.”

 

Posted in Uncategorized | Tagged , , , , , , | Leave a comment